Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01923168
Title Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals

Her2-receptor negative breast cancer


Buparlisib + Letrozole


Alpelisib + Letrozole

Age Groups: adult
Covered Countries USA | ITA | ESP | DEU | CAN | BEL | AUT

No variant requirements are available.